Publications

Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM) →

Maignan K, Backenroth D, McQuarrie NA, Lipitz NG, Williams E, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma →

Hong JL, Crossland V, Galaznik A, Dolin P

December 2018

Abstract

American Society of Hematology Annual Meeting

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM →

Chari A

December 2018

Abstract

Blood Journal

Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States →

Cetin K, McGrath L, Overman R, Reams D, Sharma A, Brookhart MA, Altomare I, Wasser JS

December 2018

Abstract

Blood Journal

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies →

Li B, Ren K, Shen L, Hou P, Sun Z, Di Bacco A, Hong JL, Galaznik A, Dash AB, Crossland V, Dolin P, Szalma S

December 2018

Abstract

Blood Journal

Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis →

Chari A, Ung B, Tian M, Agarwal A, Parikh K

December 2018

Abstract

Blood Journal

Comparative Efficacy Of Nivolumab±ipilimumab Versus Standard of Care (SOC) For Third-Line (3L) Patients with Recurrent Small Cell Lung Cancer (SCLC) Using Population-Adjusted Indirect Comparison →

Cope S, Popoff E, Keeping S, Goldgrub R, Jansen JP, Penrod J, Abraham P, Camidge DR, Korytowsky B, Gu T, Schoenherr N, Juarez-Garcia A, Le T, Yuan Y

November 2018

Abstract

EU ISPOR

Real-World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences, and Survival of ALK Inhibitor-Treated Patients →

Davies J, Martinec M, Coudert M, Delmar P, Crane G

November 2018

Manuscript

Current Medical Research and Opinion

Treatment Sequencing and Survival Outcomes in BRAF Mutation–Positive Metastatic Melanoma Patients Treated With Immunotherapy in Routine Clinical Practices in the United States →

Sadetsky N, Chuo J, McKenna E, Troutman S, Colburn D, Atkins MB

October 2018

Abstract

Society of Melanoma Research

Adjuvant Therapy is Associated with Improved Overall Survival in Advanced Melanoma Patients in the United States →

Gu T, Le T, Moshyk A, Gooden K, Kotapati S

October 2018

Abstract

Society of Melanoma Research

Real-World (RW) Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma (MEL): Subgroup Analysis of a Retrospective Cohort Study →

Freeman M, Gupte-Singh K, You M, Le TK, Ritchings C, Rao S, Jang S

October 2018

Abstract

Society of Melanoma Research

Establishing the Need for Immuno-Oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC) →

Schwartzberg L

October 2018

Abstract

ESMO Annual Congress

Real-World Dosing Patterns of Patients (Pts) With Metastatic Pancreatic Cancer (MPC) Treated With Liposomal Irinotecan (Nal-iri) in US Oncology Clinics →

Ahn D, Barzi A, Miksad RA, Surinach A, Corvino F, Valderrama A, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS

October 2018

Abstract

ESMO Annual Congress

Flatiron-authored

Assessment of Real-World Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma: A Retrospective Cohort Study →

Freeman M

October 2018

Abstract

ESMO Annual Congress

Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (MBC) Patients (pts) with Germline BRCA Mutation (gBRCAm) →

Quek R

October 2018

Abstract

ESMO Annual Congress

Comparative Effectiveness of Nab-Paclitaxel vs. Paclitaxel Monotherapy as First-Line (1L) Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC) in US Clinical Practice →

Luhn T

October 2018

Abstract

ESMO Annual Congress

Clinical Outcome with Radium-223 (Ra-223) in Patients (pts) Previously Treated with Abiraterone (Abi) or Enzalutamide (Enza): A Retrospective Study of Real-World (RW) Data from pts with Metastatic Castration-Resistant Prostate Cancer (mCRPC) →

Higano C

October 2018

Abstract

ESMO Annual Congress

Match-Adjusted Indirect Comparison of Durvalumab and Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma (UC) Following Failure of Platinum-Based Therapy →

Hoyle C

October 2018

Abstract

ESMO Annual Congress

Brain Metastases in Primary Ovarian Cancer: Real-World Data →

Ratner E

October 2018

Abstract

ESMO Annual Congress

Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study →

Liu F

October 2018

Abstract

ESMO Annual Congress

Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC) →

Jahanzeb M

October 2018

Abstract

ESMO Annual Congress

Identification of Genomic Markers of Sensitivity and Resistance to Checkpoint Inhibitors in Non-Small Cell Lung Cancer in a Real World Clinico-Genomic Database →

Murugesan K

October 2018

Abstract

ESMO Annual Congress

ALK Testing Trends and Patterns Among Community Practices in the United States →

Illei P, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens M

October 2018

Manuscript

JCO Precision Oncology

Accelerating Anticancer Drug Development — Opportunities and Trade-offs →

Nass S, Rothenberg M, Pentz R, Hricak H, Abernethy AP, Anderson K, Gee A, Harvey RD, Piantadosi S, Bertagnolli M, Schrag D, Schilsky R

October 2018

Manuscript

Nature Reviews Clinical Oncology

Flatiron-authored

Treatment Patterns and Outcomes for Patients with Advanced Melanoma in US Oncology Clinical Practices →

Whitman E, Liu F, Cao X, Diede SJ, Haiderali A, Abernethy AP

September 2018

Manuscript

Future Medicine

Flatiron-authored

Distinctive Clinical Characteristics of SCLC in Never-Smokers →

Mian I, Nichols S, Abernethy AP, Carson K, Maignan K, Torres AZ, Snider J, Frampton G, Li G, Sharon E, Szabo E, Thomas A

September 2018

Abstract

World Conference on Lung Cancer

Flatiron-authored

Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer →

Clarke JM, Stefaniak VJ, Batus M, Winfree KB, Molife C, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) →

Chalmers AW, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W

September 2018

Abstract

World Conference on Lung Cancer

Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients →

Batus M, Molife C, Clarke JM, Stefaniak VJ, Winfree KB, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC) →

Schwartzberg L, Korytowsky B, Penrod J, Yuan Y, Gu T, Le TK, Abraham P, Selvaggi G

September 2018

Abstract

World Conference on Lung Cancer

Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients →

Barlesi F, Paz-Ares L, Page D, Shewade A, Lambert P, Mughal T, Gay L, Khorshid M, Arnieri B, Capra W, Foser S, Mascaux C, Bubendorf L, Wang L

September 2018

Abstract

World Conference on Lung Cancer

Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs →

Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh MS, Chehab N, Subramanian J

September 2018

Abstract

World Conference on Lung Cancer

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Nussbaum N, Ahern E, Dougall WC, Smyth MJ

September 2018

Manuscript

OncoImmunology

Flatiron-authored

The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database →

Carrigan G, Whipple S, Taylor M, Torres AZ, Gossai A, Arnieri B, Tucker M, Hofmeister PP, Lambert P, Griffith S, Capra W

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT)

Carrigan G, Whipple S, Capra W, Taylor M, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in a Real World Oncology Database →

Black J, Castro F, Lundberg L, Marino M, Niks R, Rozinat A

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma →

Black J, Ogbu U, Wassner Fritsch E, Byon J, Yi J, Lu M

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival →

Bretscher MT, Sanglier T

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Setting →

Presley C, Tang D, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Zhu W, Nussbaum N, Sorg R, Agarwala V, Abernethy AP, Gross C

August 2018

Manuscript

JAMA

Flatiron-authored

Patterns of Bisphosphonate Treatment Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the USA: Observations from Real-World Data →

Kim C, Hernandez RK, Cyprien L, Liede A, Cheng P

August 2018

Manuscript

Supportive Care in Cancer

Disparities in the use of programmed death 1 immune checkpoint inhibitors →

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Comparative Effectiveness from a Single-Arm Trial and Real-World Data: Alectinib versus Ceritinib →

Davies J, Martinec M, Delmar P, Coudert M, Bordogna W, Golding S, Reynaldo M, Crane G

June 2018

Manuscript

Future Medicine

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Cost-Effectiveness of Multi-Gene Panel Sequencing (MGPS) for Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients →

Steuten LM, Goulart B, Meropol N, Pritchard D, Ramsey SD

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Diffusion of Innovation in Oncology: A Case Study of Immuno-Oncology (IO) Adoption for Advanced Non-Small Lung Cancer (aNSCLC) Patients Across Practices in the US →

Bennette CS, Torres AZ, Tucker M, Khozin S, Abernethy AP, Brown NR, Meropol N

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Application of a Real World Endpoint to Identify and Characterize Genetic Profiles of Patients (pts) with Poor Prognosis in Advanced Non-Small-Cell Lung Cancer (aNSCLC) →

Crane G, Trunzer K, Whipple S, Cuenco K, Tolson J, Kathuria B, Das-Gupta A

June 2018

Abstract

ASCO Annual Meeting

Real-World (RW) Characteristics, Treatment (tx) Patterns, and Overall Survival (OS) in US Patients (pts) with Metastatic Breast Cancer (mBC) and CNS Metastases (CNS mets) →

Shewade A, Fu-Chi Hsieh A, Mani A, Al-Sakaff N, Sanglier T, Taylor M, Heinzmann D

June 2018

Abstract

ASCO Annual Meeting

Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies

Lu M, Sadetsky N, Lambert P, Whipple S, Taylor M, Riehl T, Riely GJ

June 2018

Abstract

ASCO Annual Meeting

Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer →

Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Immune Checkpoint Inhibitor (ICI) Treatment in Advanced Melanoma (aMel) Patients (pts) with Renal or Hepatic Dysfunction (dysf): Real-World Patient Characteristics and Outcomes →

Spillane S, Abernethy AP, Brown NR, Freedman AN, Lenis D, Maignan K, Mariotto A, Miksad RA, Torres AZ, Sharon E

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored